Quantitative uptake in 99m Tc-EDDA/HYNIC-TOC somatostatin receptor imaging - the effect of long-acting release somatostatin analogue therapy.
Journal
Nuclear medicine communications
ISSN: 1473-5628
Titre abrégé: Nucl Med Commun
Pays: England
ID NLM: 8201017
Informations de publication
Date de publication:
01 Nov 2023
01 Nov 2023
Historique:
medline:
13
10
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
ppublish
Résumé
Withdrawal of long-acting release somatostatin analogue (LAR-SSA) treatment before somatostatin receptor imaging is based on empirical reasoning that it may block uptake at receptor sites. This study aims to quantify differences in uptake of 99m Tc-EDDA/HYNIC-TOC between patients receiving LAR-SSA and those who were not. Quantification of 177 patients (55 on LAR-SSA) imaged with 99m Tc-EDDA/HYNIC-TOC was performed, with analysis of pathological tissue and organs with physiological uptake using thresholded volumes of interest. Standardised uptake values (SUVs) and tumour/background (T/B) ratios were calculated and compared between the two patient groups. SUVs were significantly lower for physiological organ uptake for patients on LAR-SSA (e.g. spleen: SUV max 13.3 ± 5.9 versus 33.9 ± 9.0, P < 0.001); there was no significant difference for sites of pathological uptake (e.g. nodal metastases: SUV max 19.2 ± 13.0 versus 17.4 ± 11.5, P = 0.552) apart from bone metastases (SUV max 14.1 ± 13.5 versus 7.7 ± 8.0, P = 0.017) where it was significantly higher. LAR-SSA has an effect only on physiological organ uptake of 99m Tc-EDDA/HYNIC-TOC, reducing uptake. It has no significant effect on pathological uptake for most sites of primary and metastatic disease. This should be taken into account if making quantitative measurements, calculating T/B ratios or assigning Krenning Scores. There is the potential for improved dosimetric results in Peptide Receptor Radionuclide Therapy by maintaining patients on LAR-SSA.
Identifiants
pubmed: 37578312
doi: 10.1097/MNM.0000000000001746
pii: 00006231-990000000-00185
doi:
Substances chimiques
Receptors, Somatostatin
0
Organotechnetium Compounds
0
EDDA
5657-17-0
Technetium
7440-26-8
Somatostatin
51110-01-1
Radiopharmaceuticals
0
Octreotide
RWM8CCW8GP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
944-952Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. Endocr Relat Cancer 2004; 11:1–18.
Van Der Zwan JM, Trama A, Otter R, Larrañaga N, Tavilla A, Marcos-Gragera R, et al.; RARECARE WG. Rare neuroendocrine tumours: results of the surveillance of rare cancers in Europe project. Eur J Cancer 2013; 49:2565–2578.
Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA. Eur J Nucl Med Mol Imaging 2017; 44:1588–1601.
Breeman WA, De Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PP, et al. Somatostatin receptor-mediated imaging and therapy: Basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001; 28:1421–1429.
Polatom. TEKTROTYD 16 micrograms kit summary of product characteristics. 2019. https://mhraproducts4853.blob.core.windows.net/docs/a48b6388d64755814c678be4addf93cc4877f79d [Accessed 3 August 2023]
Decristoforo C, Mather SJ, Cholewinski W, Donnemiller E, Riccabona G, Moncayo R. (99m)Tc-EDDA/HYNIC-TOC: A new (99m)Tc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours: first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med 2000; 27:1318–1325.
Gabriel M, Decristoforo C, Donnemiller E, Ulmer H, Rychlinski CW, Mather SJ, et al. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med 2003; 44:708–716.
Zaknun JJ, Bodei L, Mueller-Brand J, Pavel ME, Baum RP, Hörsch D, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2013; 40:800–816.
Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996; 38:430–438.
Guillermet-Guibert J, Lahlou H, Cordelier P, Bousquet C, Pyronnet S, Susini C. Physiology of somatostatin receptors. J Endocrinol Invest 2005; 28:5–9. http://www.ncbi.nlm.nih.gov/pubmed/16625838 . [Accessed 1 November 2021]
Pavel M, O’Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, et al.; Vienna Consensus Conference participants. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 2016; 103:172–185.
Anthony L, Freda PU. From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Curr Med Res Opin 2009; 25:2989–2999.
Hope TA, Allen-Auerbach M, Bodei L, Calais J, Dahlbom M, Dunnwald LK, et al. SNMMI procedure Standard/EANM practice guideline for SSTR PET: imaging neuroendocrine tumors. J Nucl Med 2023; 64:204–210.
Janson ET, Kälkner KM, Eriksson B, Westlin JE, Öberg K. Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumors. Nucl Med Biol 1999; 26:877–882.
Ayati N, Lee ST, Zakavi R, Pathmaraj K, Al-Qatawna L, Poon A, et al. Long-acting somatostatin analog therapy differentially alters 68 Ga-DOTATATE uptake in normal tissues compared with primary tumors and metastatic lesions. J Nucl Med 2018; 59:223–227.
Cherk MH, Kong G, Hicks RJ, Hofman MS. Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression. Cancer Imaging 2018; 18:1–9.
Velikyan I, Sundin A, Eriksson B, Lundqvist H, Sörensen J, Bergström M, et al. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours - impact of peptide mass. Nucl Med Biol 2010; 37:265–275.
Li Y, Xu J, Xu X, Zhang J, Zhang Y. Long-acting octreotide treatment has no impact on tumor uptake of 99mTc-HYNIC-TOC in patients with neuroendocrine tumors. Nucl Med Commun 2019; 40:1005–1010.
Morland D, Laures N, Triumbari EKA, Perrier M, Imperiale A, Annunziata S, et al. Impact of cold somatostatin analog administration on somatostatin receptor imaging. Clin Nucl Med 2023; 48:467–473.
Kim Y, Yoo C, Oh SJ, Lee SJ, Kang J, Hwang HS, et al. Tumour-to-liver ratio determined by [68Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours. EJNMMI Res 2020; 10:10–63.
Hicks RJ, Dromain C, de Herder WW, Costa FP, Deroose CM, Frilling A, et al. ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. J Neuroendocrinol 2022; 34:1–10.
Hennrich U, Kopka K. Lutathera®: the first FDA-and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals 2019; 12.
Werner RA, Bundschuh RA, Bundschuh L, Javadi MS, Higuchi T, Weich A, et al. Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications. Ann Nucl Med 2018; 32:512–522.
Nioche C, Orlhac F, Boughdad S, Reuze S, Goya-Outi J, Robert C, et al. A freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res 2018; 78:4786–4789.
Bashir U, Azad G, Siddique MM, Dhillon S, Patel N, Bassett P, et al. The effects of segmentation algorithms on the measurement of 18F-FDG PET texture parameters in non-small cell lung cancer. EJNMMI Res 2017; 7:1–9.
Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50:122S–150S.
R Core Team. R: a language and environment for statistical computing. 2021. https://www.r-project.org/ . [Accessed 1 March 2022]
Wickham H. ggplot2: elegant graphics for data analysis. Springer-Verlag New York; 2016. https://ggplot2.tidyverse.org . [Accessed 21 August 2021]
Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, et al.; Antibes Consensus Conference participants. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine and hybrid imaging. Neuroendocrinology 2017; 105:212–244.
Antonijoan RM, Barbanoj MJ, Cordero JA, Peraire C, Obach R, Vallès J, et al. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. J Pharm Pharmacol 2010; 56:471–476.
Chen T, Miller TF, Prasad P, Lee J, Krauss J, Miscik K, et al. Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. J Clin Pharmacol 2000; 40:475–481.
Kunikowska J, Lewington V, Krolicki L. Optimizing somatostatin receptor imaging in patients with neuroendocrine tumors: The impact of99mTc-HYNICTOC SPECT/SPECT/CT versus68Ga-DOTATATE PET/CT upon clinical management. Clin Nucl Med 2017; 42:905–911.
De Camargo Etchebehere ECS, De Oliveira Santos A, Gumz B, Vicente A, Hoff PG, Corradi G, et al. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial. J Nucl Med 2014; 55:1598–1604.
Reilly C, Gemmell AJ, McLaughlin IM, Fleming R, Reed N, McIntosh D, et al. Characterisation of 99mTc EDDA/HYNIC-TOC (Tektrotyd) physiological and neuroendocrine tumour uptake using SPECT/CT standardised uptake values: initial experience. Nucl Med Commun 2021; 42:935–939.
Kuyumcu S, Özkan ZG, Sanli Y, Yilmaz E, Mudun A, Adalet I, et al. Physiological and tumoral uptake of 68Ga-DOTATATE: standardized uptake values and challenges in interpretation. Ann Nucl Med 2013; 27:538–545.
Prasad V, Baum RP. Biodistribution of the Ga-68 labeled somatostain analogue DOTA-NOC in patients with neuroendocrine tumors. Q J Nucl Med Mol Imaging 2010; 54:61–67.
Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, et al. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT. Eur J Nucl Med Mol Imaging 2013; 40:514–523.